Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 25;28(7):1461–1467. doi: 10.1038/s41591-022-01840-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — Risks are plotted by care setting of the acute phase of the disease (not hospitalized, hospitalized, and admitted to the intensive care unit). Incident outcomes were assessed from 30 days after the positive SARS-CoV-2 test to end of follow-up. Results are in comparison of breakthrough SARS-CoV-2 infection (non-hospitalized n=30,273; hospitalized n=3,667; admitted to ICU n=811) to the contemporary control group that consisted of those with no record of a positive SARS-CoV-2 test (n=4,983,491). Adjusted hazard ratios (dots) and 95% confidence intervals (error bars) are presented. Outcomes that occurred in less than 10 participants in a group were excluded.